Moderna mFLUSIVA Gets FDA Approval for Adults 50+

The US Food and Drug Administration approved Moderna’s mFLUSIVA on August 5, 2026, for adults aged 50 and older, making it the first mRNA-based seasonal influenza vaccine cleared in the United States.

The decision gives older adults another flu-shot option for the 2026–27 respiratory virus season and extends messenger RNA technology beyond Covid-19 vaccination. Moderna says it expects mFLUSIVA to be available to eligible US adults during the coming season, although first-year availability may differ by pharmacy, health system and insurer.

What is mFLUSIVA and who can receive it?

mFLUSIVA, developed as mRNA-1010, is a trivalent vaccine designed to protect against influenza A/H1N1, influenza A/H3N2 and the B/Victoria lineage.

Instead of growing influenza virus in eggs, the vaccine uses messenger RNA to give cells temporary instructions for making selected flu proteins. The immune system then learns to recognize those proteins. The mRNA does not enter the cell nucleus and is broken down after the instructions are delivered.

The FDA granted traditional approval for adults aged 50 to 64. For adults 65 and older, the agency used accelerated approval based on immune-response data, with continued approval tied to additional evidence confirming clinical benefit.

What did Moderna’s Phase 3 trial show?

Moderna’s pivotal Phase 3 study enrolled 40,703 adults aged 50 and older and compared mFLUSIVA with licensed standard-dose influenza vaccines.

In that study, mFLUSIVA showed 26.6% relative vaccine efficacy compared with the standard-dose vaccines. That figure does not mean the shot prevented only 26.6% of flu cases. It means qualifying influenza illness occurred less often in the mFLUSIVA group than in the comparison group.

Moderna also reported a 47.9% relative reduction in influenza cases that required hospitalization, emergency-room care or urgent medical treatment.

Real-world performance can still vary from one flu season to another because protection depends partly on circulating strains, vaccine matching, age and individual immune response.

Why was approval different for adults 65 and older?

For people 65 and older, US public-health guidance has generally favored enhanced flu vaccines such as high-dose, adjuvanted or recombinant options. That made the choice of comparator in Moderna’s development programme an important regulatory issue.

Moderna’s large efficacy trial used standard-dose vaccines, while a separate Phase 3 study involving nearly 3,000 adults aged 65 and older compared immune responses with a high-dose flu vaccine.

The FDA accepted the immune-response evidence under its accelerated approval pathway, but required a confirmatory study to determine whether the response translates into clinical protection against influenza disease in this age group.

The agency’s August 5 approval letter requires Moderna to conduct a pragmatic randomized study comparing mRNA-1010 with a high-dose influenza vaccine in US adults aged 65 and older.

Why did the FDA review become controversial?

Moderna’s application reached the FDA in December 2025, but the review later became unusual after regulators initially refused to consider the submission over concerns about the evidence supporting use in older adults.

The FDA subsequently resumed the review after Moderna and the agency revised the regulatory approach. On June 18, 2026, the FDA’s Vaccines and Related Biological Products Advisory Committee voted unanimously that the vaccine’s benefits outweighed its risks for adults aged 50 to 64 and separately for adults aged 65 and older.

The earlier reversal had already drawn attention from investors because the flu programme is an important part of Moderna’s effort to expand beyond Covid-19 products. The episode added an unusual regulatory chapter to a vaccine programme that later returned to formal FDA review and ultimately won approval.

What is known about safety?

FDA and Moderna documents describe a safety database covering tens of thousands of adults aged 50 and older. Common reactions included injection-site pain, fatigue, headache, muscle pain, joint pain, chills, nausea or vomiting and fever.

Most vaccine reactions reported in trials were temporary. As with other newly approved vaccines, safety monitoring will continue after launch as the product is used in a larger and more varied population.

People who have had a severe allergic reaction to a vaccine ingredient, Guillain-Barré syndrome after a previous flu shot, or conditions affecting immune response should discuss vaccination with a healthcare professional.

Official indication and safety information is available on Moderna’s mFLUSIVA information page.

How is mFLUSIVA different from traditional flu vaccines?

Many seasonal flu vaccines are manufactured using influenza viruses grown in chicken eggs. That process requires strain selection and production planning well before the vaccination season.

mRNA manufacturing does not require growing the influenza virus in eggs. The platform can potentially shorten parts of the production process and may give manufacturers more flexibility when updating vaccine strains.

That does not guarantee better protection every season. Vaccine effectiveness still depends on how well selected strains match the viruses that eventually circulate.

The broader public-health role of seasonal vaccination and efforts to improve access are explored in this overview of global vaccine access and immunization progress.

When could mFLUSIVA reach pharmacies?

Moderna says it expects the vaccine to be available in the United States for eligible adults during the 2026–27 respiratory virus season. Some doses could reach selected retailers earlier than others because many flu-vaccine purchasing agreements are made months in advance.

FDA approval also does not automatically determine insurance coverage or pharmacy availability. Recommendations from US immunization authorities, purchasing contracts and individual health-plan rules can influence how quickly a new vaccine becomes widely accessible.

Moderna is also seeking regulatory decisions for mFLUSIVA outside the United States, including in the European Union, Canada and Australia.

Why the approval matters for Moderna

mFLUSIVA gives Moderna another approved respiratory product at a time when the company is trying to build more durable revenue sources beyond pandemic-era Covid-19 vaccine demand.

The company is also developing combination respiratory vaccines. A standalone flu approval strengthens the clinical and manufacturing foundation for that strategy, although any combination product must still meet separate regulatory requirements.

The commercial importance of new respiratory products can be seen in the wider picture around Moderna’s revenue outlook and vaccine pipeline.

What the approval means for adults 50 and older

mFLUSIVA adds a new option rather than replacing the flu vaccines already available in the United States. Adults 65 and older in particular already have access to high-dose, adjuvanted and recombinant vaccines that are designed for stronger protection in older age groups.

The new mRNA shot therefore enters an established market rather than creating a one-size-fits-all replacement. The most appropriate flu vaccine will depend on age, health history, current recommendations, local availability and advice from a qualified healthcare professional.

For Moderna, the approval is a major regulatory milestone. For patients, its longer-term importance will depend on how the vaccine performs across multiple flu seasons and on the results of the required confirmatory study in adults aged 65 and older.